arXiv:2606.00555v2 Announce Type: replace Abstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives -- binding affinity and druggability -- which single optimization steps rarely improve together. To quantify this...
Läs hela artikeln hos källan.
Kommentarer (0)
Inga kommentarer ännu. Bli först med att kommentera!